OGEN— ORAGENICS INC

MaterialsBiotechnology$2M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Research and development	$2.4M-41.8%	$4.1M-73.4%	$15.5M+53.8%	$10.1M
General and administrative	$7.0M+8.2%	$6.4M+18.2%	$5.5M+21.7%	$4.5M
Total operating expenses	$9.4M-11.3%	$10.6M-49.6%	$20.9M+43.9%	$14.6M
Loss from operations	-$9.4M+11.3%	-$10.6M+49.5%	-$20.9M-45.0%	-$14.4M
Interest income	$182K+297.0%	$46K-78.2%	$210K+54.8%	$136K
Interest expense	-$786K-2534.9%	-$30K+2.5%	-$31K-102.5%	-$15K
Foreign currency exchange, net	-$13K+47.6%	-$25K	—	—
Total other income (expense), net	-$617K-6676.8%	-$9K-103.7%	$249K+88.2%	$132K
Loss before income taxes	-$10.0M+5.6%	-$10.6M+48.8%	-$20.7M-44.6%	-$14.3M
Income tax benefit	$137K	—	—	—
Net loss	-$9.8M+6.9%	-$10.6M+48.8%	-$20.7M-44.6%	-$14.3M
Basic net loss per share	-$4.56+90.5%	-$47.88-421.6%	-$9.18-29.1%	-$7.11
Diluted net loss per share	-$4.56+90.5%	-$47.88-421.6%	-$9.18-29.1%	-$7.11
Weight average shares outstanding, basic	2.2M-67.4%	6.6M+194.3%	2.2M+12.0%	2.0M
Weight average shares outstanding, diluted	2.2M-67.4%	6.6M+194.3%	2.2M+12.0%	2.0M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.